Collegium Pharmaceutical (NASDAQ:COLL) Given “Buy” Rating at Needham & Company LLC

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by stock analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They presently have a $46.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target points to a potential upside of 81.03% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Down 7.2 %

COLL stock opened at $25.41 on Wednesday. The company has a market capitalization of $816.47 million, a PE ratio of 10.95 and a beta of 0.76. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical has a 12 month low of $25.17 and a 12 month high of $42.29. The firm’s 50-day moving average is $29.60 and its 200 day moving average is $31.89.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, research analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Colleen Tupper sold 977 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the transaction, the chief financial officer now directly owns 164,269 shares in the company, valued at approximately $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 109,193 shares of company stock valued at $3,243,594. Corporate insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company’s stock valued at $522,000 after purchasing an additional 339 shares during the last quarter. AlphaQuest LLC boosted its stake in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after purchasing an additional 374 shares in the last quarter. Foundry Partners LLC grew its position in Collegium Pharmaceutical by 2.4% during the 4th quarter. Foundry Partners LLC now owns 16,162 shares of the specialty pharmaceutical company’s stock worth $463,000 after purchasing an additional 381 shares during the last quarter. Finally, Gallacher Capital Management LLC increased its stake in Collegium Pharmaceutical by 3.3% during the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after purchasing an additional 470 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.